October 15, 2026: The Therapeutic Toolkit: Mechanisms, Efficacy, and Safety of Biologics and Small Molecules

October 15, 2026

Welcome to the second session of this ECHO program!


Claiming Credit 
Thank you for attending the session on October 15th, 2026. Once logged in, please click on "Take Course" on the right-hand side and your enrollment will be recorded. You will be prompted to claim your credit on the following page

Target Audience
This ECHO® series is designed for gastroenterologists, NPs, PAs, nurses, and pharmacists in community and academic GI practices. Teams and individual GI providers are welcome to attend!

Learning Objectives:
At the conclusion of this learning activity, participants will be better able to:

  1. Recognize advanced therapeutic options and exhibit a comprehensive understanding of the pharmacodynamics, efficacy, and safety profile of current and emerging IBD treatments, including biologics, and small molecule inhibitors.
  2. Tailor treatment to patient-specific presentation: select the most appropriate therapy based on IBD phenotype, behavior, severity, presence of complications, and patient preferences.

Grantor Acknowledgement:
Supported by educational grants from AbbVie, AudioDigest Foundation, Celltrion USA, Janssen Biotech, administered by Janssen Scientific Affairs LLC, and Takeda Pharmaceuticals U.S.A.,Inc.

Course summary

Available credit: 
  • 1.00 AAPA Category I CME
  • 1.00 ABIM Medical Knowledge
  • 1.00 ACPE Pharmacy
  • 1.00 AMA PRA Category 1 Credit™

    Boston University Chobanian & Avedisian School of Medicine designates this Live activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • 1.00 ANCC
    • 1.00 ANCC Pharmacology
  • 1.00 Participation
Course opens: 
10/15/2026
Course expires: 
10/15/2027
Event starts: 
10/15/2026 - 7:00pm EDT
Event ends: 
10/15/2026 - 8:00pm EDT
Add to calendar: 
Rating: 
0

Jeremy KW Spiewak, PharmD MCSR-RPh MSCS
Ambulatory Care Clinical Pharmacy Specialist
Collaborative Practice Pharmacist
Adjunct Faculty Pharmacy Practice MCPHS University
Affiliate Professor of Pharmacy Northeastern University School of Pharmacy
Lahey Inflammatory Bowel Disease Center
Division of Gastroenterology

Dr. Jeremy Spiewak is a clinical pharmacist in Burlington, MA. He is part of BILH Department of Gastroenterology and serves as an ambulatory care pharmacist specializing in the longitudinal follow up and management of patients with Inflammatory Bowel Disease. He has operated in multiple sectors of the practice of pharmacy since 2002, specifically community pharmacy, specialty pharmacy, investigational drug services, regulatory affairs, pharmacist consultant, and academia as adjunct faculty at MCPHS University and Boston University School of Medicine.

Dr. Spiewak is a speaker, consultant, and on the advisory panels for Abbvie, Celltrion, and Johnson & Johnson.

 

Off-Label Discussion: Dr. Spiewak will discuss the unlabeled/investigational uses of Infliximab, upadacitinib, Icotrokinra, risankizumab, adalimumab, golimumab, zymfentra, certolizumab, prednisone, ustekinumab, vedolizumab, and mirikizumab.

 

Planning Committee

The following planning committee members have no relevant financial relationships to disclose.

  • Linda Baer, MSPH, CHCP; BU CCE Associate Director
  • Juanita Belton, PA; Physician Associate Accreditation Reviewer
  • Michael Burk, BS; BU CCE Senior Operations Manager
  • Amy Donegan , APRN, CPNP-PC; Member of the BU Hub Team and Nursing Accreditation Advisor
  • Sharmeel Wasan, MD; Program Course Director

 

Dr. Spiewak, PharmD, MCSR-RPh, MSCS; ACPE Accreditation Advisor, discloses that he is a speaker, consultant, and on the advisory panels for Abbvie, Celltrion, and Johnson & Johnson.

Ms. Rocio Castrillon, MBA, is a patient consultant for Boehringer Ingelheim, Cristcot, EPI-Q, Inc., and Janssen Biotech, Inc. and is on a patient steering committee for Genentech.

Disclosure Policy

Boston University Chobanian & Avedisian School of Medicine asks all individuals involved in the development and presentation of Accredited Continuing Education activities to disclose all financial relationships with ineligible companies. This information is disclosed to all activity participants prior to the start of the educational activity. Boston University Chobanian & Avedisian School of Medicine has procedures to mitigate all relevant financial relationships with ineligible companies. In addition, faculty members are asked to disclose when any unapproved use of pharmaceuticals and devices is being discussed. 
 

In accordance with the Standards for Integrity and Independence in Accredited Continuing Education, all relevant financial relationships that faculty, planners, authors, and anyone who may be in control of content have with ineligible companies have been mitigated.
 

Disclaimer Policy

THESE MATERIALS AND ALL OTHER MATERIALS PROVIDED IN CONJUNCTION WITH CONTINUING EDUCATION ACTIVITIES ARE INTENDED SOLELY FOR PURPOSES OF SUPPLEMENTING CONTINUING EDUCATION PROGRAMS FOR QUALIFIED HEALTH CARE PROFESSIONALS.  ANYONE USING THE MATERIALS ASSUMES FULL RESPONSIBILITY AND ALL RISK FOR THEIR APPROPRIATE USE.  TRUSTEES OF BOSTON UNIVERSITY MAKES NO WARRANTIES OR REPRESENTATIONS WHATSOEVER REGARDING THE ACCURACY, COMPLETENESS, CURRENTNESS, NONINFRINGEMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OF THE MATERIALS.  IN NO EVENT WILL TRUSTEES OF BOSTON UNIVERSITY BE LIABLE TO ANYONE FOR ANY DECISION MADE OR ACTION TAKEN IN RELIANCE ON THE MATERIALS.  IN NO EVENT SHOULD THE INFORMATION IN THE MATERIALS BE USED AS A SUBSTITUTE FOR PROFESSIONAL CARE.  IN NO EVENT SHOULD INFORMATION IN THE MATERIALS REGARDING LAWS, REGULATIONS, OR LEGAL LIABILITY BE CONSIDERED LEGAL ADVICE OR USED AS A SUBSTITUTE FOR CONSULTING WITH AN ATTORNEY.

Accreditation Statement
This activity is developed by Boston University Chobanian & Avedisian School of Medicine.

In support of improving patient care, Boston University Chobanian & Avedisian School of Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

 

 

Physician Accreditation
Boston University Chobanian & Avedisian School of Medicine designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
 

American Board of Internal Medicine Maintenance of Certification (MOC) Part 2 Credit

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.


By participating and claiming credit, you agree to BU sharing your information with ACCME PARS, the data conduit to the ABIM.
 

Nurse Accreditation
Nursing Contact Hours: 1.0 of which 1.0 are eligible for pharmacology credit.
 

Physician Associate Accreditation

Boston University Chobanian & Avedisian School of Medicine has been authorized by the American Academy of Physician Associates (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. PAs should only claim credit commensurate with the extent of their participation.

 

 

Pharmacy Accreditation

This activity is approved for 1.0 CPE credit(s) under the ACPE universal activity number UAN JA0000185-0000-26-042-L01-P. The activity is available for credit claiming through 12/14/26

 

 

IPCE Accreditation

This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.

 

 

Questions: If you have any questions about the program, registering or claiming credit please write [email protected] and your questions will be answered. 

Available Credit

  • 1.00 AAPA Category I CME
  • 1.00 ABIM Medical Knowledge
  • 1.00 ACPE Pharmacy
  • 1.00 AMA PRA Category 1 Credit™

    Boston University Chobanian & Avedisian School of Medicine designates this Live activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • 1.00 ANCC
    • 1.00 ANCC Pharmacology
  • 1.00 Participation
Please login or register to take this course.